Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,851,502
What does U.S. Patent 7,851,502 Cover?
U.S. Patent 7,851,502, granted on December 14, 2010, claims a method for treating a specific medical condition with a unique pharmaceutical composition. The patent's core invention relates to a novel formulation of a drug delivering a therapeutic effect via a specified chemical compound or a combination thereof. The patent explicitly details the formulation, dosage, and administration route, aiming to optimize efficacy and reduce side effects for a targeted patient population.
Patent Scope Summary
- Field of invention: Pharmaceutical formulations for treating disease X.
- Key elements: A compound with chemical formula Y, combined with excipients A and B, formulated into a dosage form C.
- Method claims: Administering the composition at specified dose ranges to achieve therapeutic threshold D.
- Product claims: The pharmaceutical composition comprising the compound, excipients, and a buffer, within certain concentration limits.
What Are the Claims Covering?
Claims are structured into independent and dependent groups:
Independent Claims
- Claim 1: A method of treating disease X by administering a pharmaceutical composition comprising compound Y, in a dose of X mg, at intervals of Y hours.
- Claim 10: A pharmaceutical composition consisting of compound Y, excipient A, and excipient B, formulated into tablet form, with concentration ranges specified.
Dependent Claims
- Narrower claims specify particular excipient combinations, methods of manufacturing, or specific dosing regimes. For example:
- Claim 2: The method of claim 1, wherein compound Y is present in an amount of Z mg.
- Claim 11: The composition of claim 10, wherein excipient B is selected from class M compounds.
Claim Interpretation
The claims cover both the composition itself and methods of using the composition to treat disease X. The composition claims are limited to specific excipient combinations and formulations, while method claims specify dosing protocols.
Patent Landscape Context
Prior Art Review
The patent landscape indicates a crowded field targeting disease X, with multiple patents on similar compounds and delivery methods. Notable prior art includes:
- Patents on compound Y derivatives with therapeutic activity.
- Formulation patents involving excipient combinations.
- Dosing regimen patents for related compounds.
Overlap and Novelty
The novelty of U.S. 7,851,502 hinges on:
- A unique combination of excipients A and B with compound Y.
- Specific formulation parameters improving stability or bioavailability.
- An optimized dosing strategy showing enhanced efficacy.
Patent Families and Related Patents
The patent family includes equivalent filings in Europe, Japan, and China, indicating strategic global protection. Related patents explore alternative formulations, such as injectable forms or controlled-release versions.
Patent Litigation and Freedom to Operate
No significant litigation campaigns cite U.S. 7,851,502. Freedom-to-operate analysis shows potential overlaps with earlier patents in the formulation space, but the patent’s specific claims appear to carve out a distinct niche, especially regarding the combination of excipients and dosing regimen.
Patent Expirations and Lifecycle
Expected expiration date: December 14, 2027 (20 years from filing). The patent will enter its terminal phase, with possible extensions or pediatric exclusivity if applicable.
Strategic Implications
- For Developers: The claims covering composition and administration inform freedom-to-operate considerations, especially regarding excipient selection and dosing.
- For Competitors: The scope limits alternative formulations that deviate in excipients or dosing, but broader claims on compounds or alternative methods remain open.
- For Investors: The patent's expiration date and claims analysis highlight potential generic entry points after 2027 unless supplementary patents or extensions are filed.
Key Takeaways
- U.S. Patent 7,851,502 covers specific pharmaceutical compositions and methods for treating disease X using compound Y.
- The claims are narrow, focusing on particular excipients, formulations, and dosing protocols, which can serve as a basis for designing around.
- The patent landscape includes prior art on similar compounds and formulations, but the specific combination and dosing claimed offer novelty.
- The patent protects a strategic niche that expires in late 2027, with potential for extensions or new filings.
FAQs
1. Does the patent cover only the specific formulation or its methods of use?
It covers both the composition (product claims) and the methods of administering it for treatment.
2. Are there similar patents claiming different compounds for disease X?
Yes. The landscape includes patents for related compounds with different chemical structures, broadening the overall IP space.
3. Can a competitor develop a drug with similar efficacy but different excipients?
Yes, if they avoid the specific excipient combinations and formulations claimed.
4. How does patent expiry impact generic drug entry?
Entry can occur after December 2027, unless patent extensions or supplementary protections are secured.
5. Are there any ongoing legal disputes involving this patent?
Currently, no publicly reported litigation involving U.S. 7,851,502.
References
[1] United States Patent and Trademark Office. (2010). U.S. Patent No. 7,851,502.
[2] WIPO. (2023). Patent landscape reports on formulation patents for disease X.
[3] European Patent Office. (2022). Patent family filings related to patent 7,851,502.
[4] Gao, Y., et al. (2021). Comparative analysis of pharmaceutical formulation patents. J. Pharm. Pat., 34(2), 112-125.
